275 related articles for article (PubMed ID: 28087951)
1. A phase II study of concurrent chemoradiotherapy and erlotinib for inoperable esophageal squamous cell carcinoma.
Zhao C; Lin L; Liu J; Liu R; Chen Y; Ge F; Jia R; Jin Y; Wang Y; Xu J
Oncotarget; 2016 Aug; 7(35):57310-57316. PubMed ID: 28087951
[TBL] [Abstract][Full Text] [Related]
2. Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study.
Zhai Y; Hui Z; Wang J; Zou S; Liang J; Wang X; Lv J; Chen B; Zhu H; Wang L
Dis Esophagus; 2013 Jul; 26(5):503-9. PubMed ID: 22862289
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of concurrent chemoradiation in combination with erlotinib for locally advanced esophageal carcinoma.
Li G; Hu W; Wang J; Deng X; Zhang P; Zhang X; Xie C; Wu S
Int J Radiat Oncol Biol Phys; 2010 Dec; 78(5):1407-12. PubMed ID: 20350790
[TBL] [Abstract][Full Text] [Related]
4. Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
Hu G; Wang Z; Wang Y; Zhang Q; Tang N; Guo J; Liu L; Han X
Drug Des Devel Ther; 2016; 10():2129-36. PubMed ID: 27445460
[TBL] [Abstract][Full Text] [Related]
5. Chemoradiotherapy with extended nodal irradiation and/or erlotinib in locally advanced oesophageal squamous cell cancer: long-term update of a randomised phase 3 trial.
Xie C; Jing Z; Luo H; Jiang W; Ma L; Hu W; Zheng A; Li D; Ding L; Zhang H; Xie C; Lian X; Du D; Chen M; Bian X; Tan B; Xia B; Xie R; Liu Q; Wang L; Wu S
Br J Cancer; 2020 Nov; 123(11):1616-1624. PubMed ID: 32958820
[TBL] [Abstract][Full Text] [Related]
6. The crucial role of blood VEGF kinetics in patients with locally advanced esophageal squamous cell carcinoma receiving curative concurrent chemoradiotherapy.
Chen YH; Lu HI; Lo CM; Wang YM; Chou SY; Hsiao CC; Huang CC; Shih LH; Chen SW; Li SH
BMC Cancer; 2018 Aug; 18(1):837. PubMed ID: 30126380
[TBL] [Abstract][Full Text] [Related]
7. Randomised phase III trial of concurrent chemoradiotherapy with extended nodal irradiation and erlotinib in patients with inoperable oesophageal squamous cell cancer.
Wu SX; Wang LH; Luo HL; Xie CY; Zhang XB; Hu W; Zheng AP; Li DJ; Zhang HY; Xie CH; Lian XL; Du DX; Chen M; Bian XH; Tan BX; Jiang H; Zhang HB; Wang JH; Jing Z; Xia B; Zhang N; Zhang P; Li WF; Zhao FJ; Tian ZF; Liu H; Huang KW; Hu J; Xie RF; Du L; Li G
Eur J Cancer; 2018 Apr; 93():99-107. PubMed ID: 29494818
[TBL] [Abstract][Full Text] [Related]
8. A randomized phase 3 trial comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in Chemoradiotherapy for locally advanced esophageal carcinoma-the ESO-shanghai 1 trial protocol.
Chen Y; Zhu Z; Zhao W; Li L; Ye J; Wu C; Tang H; Lin Q; Li J; Xia Y; Li Y; Zhou J; Zhao K
Radiat Oncol; 2018 Feb; 13(1):33. PubMed ID: 29482649
[TBL] [Abstract][Full Text] [Related]
9. Promising outcomes of definitive chemoradiation and cetuximab for patients with esophageal squamous cell carcinoma.
Chen Y; Wu X; Bu S; He C; Wang W; Liu J; Guo W; Tan B; Wang Y; Wang J
Cancer Sci; 2012 Nov; 103(11):1979-84. PubMed ID: 22845557
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of simultaneous integrated boost intensity-modulated radiation therapy for esophageal squamous cell carcinoma in Chinese population: A single institution experience.
Xu Y; Wang Z; Liu G; Zheng X; Wang Y; Feng W; Lai X; Zhou X; Li P; Ma H; Wang J; Hu X; Chen M
J Cancer Res Ther; 2016 Oct; 12(Supplement):82-88. PubMed ID: 27721262
[TBL] [Abstract][Full Text] [Related]
11. Comparison of efficacy and toxicity profiles between paclitaxel/lobapoatin- and cisplatin/5-fluorouracil-based concurrent chemoradiotherapy of advanced inoperable oesophageal cancer.
Yang JS; Wang T; Qiu MQ; Li QL
Intern Med J; 2015 Jul; 45(7):757-61. PubMed ID: 25851492
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the clinical efficacy between single-agent and dual-agent concurrent chemoradiotherapy in the treatment of unresectable esophageal squamous cell carcinoma: a multicenter retrospective analysis.
Li J; Gong Y; Diao P; Huang Q; Wen Y; Lin B; Cai H; Tian H; He B; Ji L; Guo P; Miao J; Du X
Radiat Oncol; 2018 Jan; 13(1):12. PubMed ID: 29357883
[TBL] [Abstract][Full Text] [Related]
13. Preoperative low-dose weekly cisplatin and continuous infusion fluorouracil plus hyperfractionated radiotherapy in stage II-III esophageal carcinoma.
Caro M; Font A; Comas S; Viciano M; Remon J; Céliz P; Robles J; Musulén E; Sendrós MJ; Mesalles E; Jiménez JA; Boix J; Arellano A; Fernández-Llamazares J
Clin Transl Oncol; 2016 Nov; 18(11):1106-1113. PubMed ID: 26856597
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma.
Fan Y; Jiang Y; Zhou X; Chen Q; Huang Z; Xu Y; Gong L; Yu H; Yang H; Liu J; Lei T; Zhao Q; Mao W
Oncotarget; 2016 Aug; 7(31):50624-50634. PubMed ID: 27244882
[TBL] [Abstract][Full Text] [Related]
15. [Concurrent chemoradiation with paclitaxel and platinum for locally advanced esophageal cancer].
Zhang P; Xie CY; Wu SX
Zhonghua Zhong Liu Za Zhi; 2007 Oct; 29(10):773-7. PubMed ID: 18396692
[TBL] [Abstract][Full Text] [Related]
16. Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study.
Choi N; Park SD; Lynch T; Wright C; Ancukiewicz M; Wain J; Donahue D; Mathisen D
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):111-22. PubMed ID: 15337546
[TBL] [Abstract][Full Text] [Related]
17. Prospective, open, multicentre Phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and cisplatin for esophageal carcinoma.
Ma HB; Di ZL; Wen J; Ke Y; Sun X; Ren J
Jpn J Clin Oncol; 2015 Feb; 45(2):169-75. PubMed ID: 25416813
[TBL] [Abstract][Full Text] [Related]
18. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
Satake H; Tahara M; Mochizuki S; Kato K; Hara H; Yokota T; Kiyota N; Kii T; Chin K; Zenda S; Kojima T; Bando H; Yamazaki T; Iwasa S; Honma Y; Hamauchi S; Tsushima T; Ohtsu A
Cancer Chemother Pharmacol; 2016 Jul; 78(1):91-9. PubMed ID: 27193097
[TBL] [Abstract][Full Text] [Related]
19. A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma.
Wang HY; Yao ZH; Tang H; Zhao Y; Jin SL; Zhou WP; Yao SN; Yang SJ; Liu YY; Luo SX
Oncotarget; 2017 Jan; 8(5):7540-7547. PubMed ID: 27902478
[TBL] [Abstract][Full Text] [Related]
20. Long-term results of concurrent chemoradiotherapy with daily-low-dose continuous infusion of 5-fluorouracil and cisplatin (LDFP) for Stage I-II esophageal carcinoma.
Kumabe A; Fukada J; Kota R; Koike N; Shiraishi Y; Seki S; Yoshida K; Kitagawa Y; Shigematsu N
Dis Esophagus; 2018 Apr; 31(4):. PubMed ID: 29228166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
